Neoplasms

All Conditions

Respiratory Tract (Lung and Bronchial) Diseases

Carcinoma

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms

Carcinoma, Bronchogenic

Bronchial Neoplasms

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Antineoplastic Agents

All Drugs and Chemicals

Belotecan

Topoisomerase I Inhibitors

Enzyme Inhibitors

A phase II study is conducted to determine the efficacy and safety of a single agent Camtobell inj.(belotecan) on a weekly schedule in locally advanced or metastatic non-small cell lung cancer patients previously treated with chemotherapy. The usefulness of the this regimen is evaluated by response rate, median survival time, progression free survival and duration of response.

Study of Camtobell Inj (Belotecan) on Weekly Schedule in Non-small Cell Lung Cancer (NSCLC) Patients Previously Treated With Chemotherapy

Single-Arm, Open-label, Multicenter, Phase 2 Clinical Trial to Assess the Efficacy and Safety of Single-Agent Camtobell Inj.(Belotecan) Administered on A Weekly Schedule in Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients Previously Treated With Chemotherapy

Asan Medical Center

Samsung Medical Center

Seoul National University Hospital

Ulsan University Hospital

Chong Kun Dang Pharmaceutical

Rare Diseases

Small Cell Lung Carcinoma

Carcinoma, Small Cell

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Small Cell Lung Cancer

Etoposide

Cisplatin

Camptothecin

Etoposide phosphate

Belotecan : 0.5mg/㎡/day for Day 1 to 4, repeated every 3 weeks

Etoposide 100mg/㎡/day for Day 1 to 3, repeated every 3 weeks

Cisplatin 60mg/㎡/day for Day 1, repeated every 3 weeks

In-Jae Oh, M.D.,Ph.D.

Belotecan (Camtobell, CKD-602, Chong Kun Dang Pharm., Korea) is a new camptothecin derivative, that exhibits anticancer effects by inhibiting topoisomerase I. The investigators will have a randomized prospective multicenter trial of Belotecan/Cisplatin versus Etoposide/Cisplatin in patients with previously untreated, extensive-stage small cell lung cancer.

Primary endpoints

* to assess Response Rate

Secondary endpoints

* to assess Overall response duration, Time to progression, Overall survival

Trial of Belotecan/Cisplatin in Chemotherapy Naive Small Cell Lung Cancer Patient

A Randomized Prospective Multicenter Trial of Belotecan/Cisplatin Versus Etoposide/Cisplatin in Patients With Previously Untreated, Extensive-stage Small-cell Lung Cancer

Chonnam National University Hospital

Assistant Professor

Immune System Diseases

Hypersensitivity

Topotecan

1.5 mg/m\^2 IV days 1, 2, 3, 4, 5 of each 21-day cycle until 6 cycle or more

0.5 mg/m\^2 IV days 1, 2, 3, 4, 5 of each 21-day cycle until 6 cycle or more

Heung Tae Kim, M.D., Ph.D

Jin Hyoung Kang, M.D., Ph.D

Jin Young Kim, M.D., Ph.D

Dong-Wan Kim, M.D., Ph.D

Sang-We Kim, M.D., Ph.D

Hye Ryeon Kim, M.D., Ph.D

Jin Hyuk Choi, M.D., Ph.D

Ki Hyeong Lee, M.D., Ph.D

Ho Jung An, M.D., Ph.D

Chi Hoon Maeng, M.D., Ph.D

Jin-Soo Kim, M.D., Ph.D

Joung Soon Jang, M.D., Ph.D

Bong Seog Kim, M.D., Ph.D

Joo-Hang Kim, .D., Ph.D

The purpose of this study is to evaluate the efficacy and safety of Belotecan administered 5 days every 3 weeks in comparison to Topotecan in Patients with relapsed small cell lung cancer.

A Phase Ⅱb, Randomized, Open, Parallel-Group, Multi-Center Trial to Assess the Efficacy and Safety of Belotecan(CamtoBell inj.) or Topotecan in Patients with Relapsed Small Cell Lung Cancer

A Randomized Study to Compare the Efficacy and Safety of Belotecan and Topotecan as Monotherapy for Sensitive-Relapsed Small Cell Lung Cancer

A Phase IIb, Randomized, Open, Parallel-Group, Multi-Center Trial to Assess the Efficacy and Safety of Belotecan(CamtoBell Inj.) or Topotecan in Patients With Relapsed Small Cell Lung Cancer

The response rate was defined as the test subject who had a complete response (CR) or a partial response (PR) as determined by the 'tumor response evaluation' criteria specified in the research protocol

Defined as the time from the randomization to the time of death.

Defined as the elapsed time from the time of randomization to the time of confirmation of progression or the time of death

Ifosfamide

Isophosphamide mustard

Antineoplastic Agents, Alkylating

Alkylating Agents

Belotecan and Ifosfamide

Hee Kyung Ahn

Phase 1 : To evaluate MTD(Maximal tolerated dose)and DLT(Dose limiting Toxicity) of Belotecan and Ifosfamide.

Phase 2 : To analyse efficacy and toxicity of Belotecan and Ifosfamide.

A Phase Ib/II Trial of Belotecan and Ifosfamide in Patients With Extensive Disease of Small Cell Lung Cancer

Gachon University Gil Medical Center

Professor

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Study of Camtobell Inj (Belotecan) on Weekly Schedule in Non-small Cell Lung Cancer (NSCLC) Patients Previously Treated With Chemotherapy	NCT01022671	Carcinoma, Non-...	Belotecan	19 Years -	Chong Kun Dang Pharmaceutical
Trial of Belotecan/Cisplatin in Chemotherapy Naive Small Cell Lung Cancer Patient	NCT00826644	Carcinoma, Smal...	Belotecan Etoposide Cisplatin	19 Years - 80 Years	Chonnam National University Hospital
A Randomized Study to Compare the Efficacy and Safety of Belotecan and Topotecan as Monotherapy for Sensitive-Relapsed Small Cell Lung Cancer	NCT01497873	Small Cell Lung...	Topotecan Belotecan	18 Years -	Chong Kun Dang Pharmaceutical
Trial of Belotecan/Cisplatin in Chemotherapy Naive Small Cell Lung Cancer Patient	NCT00826644	Carcinoma, Smal...	Belotecan Etoposide Cisplatin	19 Years - 80 Years	Chonnam National University Hospital
A Phase Ib/II Trial of Belotecan and Ifosfamide in Patients With Extensive Disease of Small Cell Lung Cancer	NCT01784107	Small Cell Lung...	Belotecan and I...	18 Years -	Gachon University Gil Medical Center
A Randomized Study to Compare the Efficacy and Safety of Belotecan and Topotecan as Monotherapy for Sensitive-Relapsed Small Cell Lung Cancer	NCT01497873	Small Cell Lung...	Topotecan Belotecan	18 Years -	Chong Kun Dang Pharmaceutical
Trial of Belotecan/Cisplatin in Chemotherapy Naive Small Cell Lung Cancer Patient	NCT00826644	Carcinoma, Smal...	Belotecan Etoposide Cisplatin	19 Years - 80 Years	Chonnam National University Hospital

Spots Global Cancer Trial Database for belotecan

Every month we try and update this database with for belotecan cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for belotecan

Every month we try and update this database with for belotecan cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for belotecan cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.